Philippa Easterbrook is an infectious disease specialist, public health physician, epidemiologist, and researcher who has dedicated more than two decades to scale-up of the global response to the HIV epidemic, and the last 10 years also to the global elimination of hepatitis C and B infection. She is currently Visiting Professor in Faculty of Medicine at Imperial College, London. For eleven years, she was Head of Department, Professor of HIV Medicine, and consultant physician in Infectious Diseases at King´s College London, and also Head of Research at the Infectious Diseases Institute in Uganda. For the last 12 years, she has been based in the Global Hepatitis Program at the World Health Organization Headquarters in Geneva, where she has led the development and dissemination of global normative guidance for HIV as well as Hepatitis B and C testing and treatment. This includes the 2022 HCV guidelines on simplified service delivery and diagnostics and treatment of children and adolescents, the first guidance for countries on validation of viral hepatitis elimination, and the new 2024 WHO hepatitis B guidelines which substantially simplifies and expands treatment eligibility and an anticipated game-changer in promoting treatment access globally. She has also provided technical guidance to national programs in more than 20 countries worldwide on the implementation of hepatitis B and C testing and treatment. Philippa has served as a Member of the UK Medical Research Council Infection and Immunity Committee, was vice-chair of the World Health Organization Guidelines Review Committee, and an expert member of the recent UK Infected Blood Enquiry. Her HIV research has encompassed epidemiology, clinical trials, operational and qualitative research, and laboratory-based studies. In 2023, she received the WHO Director General excellence team award for support of Egypt to achieve the gold tier award on the path elimination of hepatitis C infection.

Adjunct Professor Christine Connors OAM MBBS MPH FAFPHM is an experienced public health physician, general practitioner, researcher and health service executive with more than 35 years' experience working in health care in the Northern Territory. Christine is now the Chief Health Officer for NT. Her field of expertise has been health system improvement to improve population health outcomes. This has included integration of health care delivery between remote primary health care services and hospitals, clinical guideline development, education and training, audit and quality improvement and revision of models of care. Christine was nominated by Health Ministers as a member of the National Preventative Health Taskforce 2008-2009 which produced the National Preventative Health Strategy in September 2009 Christine has been actively involved in research translation with Menzies School of Health Research, with a focus on reducing skin infections, Diabetes detection and control and quality improvement in primary care.

In addition to being recognised as a leading clinician in the management of hepatitis B, Ben serves on a range of national and international committees relating to viral hepatitis clinical management and public health responses, including the national Ministerial Advisory Committee on Blood Borne Viruses and Sexually Transmissible Infections (MACBBVS), the Hepatitis B Expert Resource Panel for the WHO Western Pacific Region, and the Global Validation Advisory Committee (GVAC) for the elimination of mother to child transmission of HIV, syphilis and hepatitis B, Global Hepatitis Programme, WHO. He has over 100 peer reviewed publications relating to viral hepatitis, and in 2015 was named the inaugural Director of the WHO Collaborating Centre for Viral Hepatitis at the Doherty Institute.

Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis epidemiological and clinical research, clinical care, and public health policy for 25 years.

Professor Margaret Hellard AM was appointed Deputy Director of the Burnet Institute in March 2017, prior to this appointment she was Head, Centre for Population Health from 2002-2017. She is Head of Hepatitis Services in the Infectious Diseases Unit at The Alfred Hospital. Margaret's principal research interests are in eliminating HIV, HCV and HBV as public health threats by 2030 by reducing the risk behaviours associated with the transmission of these diseases and improving the management of individuals who already have infection. She has considerable experience in undertaking community-based research involving young people, people who inject drugs, gay and bisexual men, and vulnerable populations. Furthermore, Margaret has supported the development of and works closely with research groups at the Burnet in sexual health, drugs and alcohol, malaria and tuberculosis. In 2020 Margaret has also undertaken research related to the impact of COVID-19, and the unintended consequence of Government restrictions due to COVID-19 on the community.

Director and founder of Inno Community Development Organisation. Inno created the most influential hotline to fight the stigma and hepatitis against people living with hepatitis in China since 2010 and extended the impact in other countries in Asia since 2019. As a person living with hepatitis at the age of 2 because of the iatrogenic infection, Dee has been experiencing discrimination and self-stigma from day one when he had the blood test. He crawled out of the pain and started to make a change. He has been active and vocal for being the: · Board member of World Hepatitis Alliance of West Pacific Region · Chair of Steering Group of International Liver Cancer Movement · Member of Patient Advocacy Committee of Global NASH Council · Member of CEVHAP

Professor Gail Matthews is Head of the Therapeutic Vaccine and Research Program (TVRP) at the Kirby Institute, UNSW as well as Head of Infectious Diseases at St Vincent’s Hospital. She has a strong background in HIV, viral hepatitis and strategic therapeutic clinical trials. As head of TVRP she leads several international clinical trials in HIV and COVID-19, as well as national projects in HCV and HBV. She works clinically as a specialist in HIV, Infectious Diseases and Viral Hepatitis at St Vincent’s Hospital, Sydney and is an NHMRC Investigator Fellow.